U.S. Stock News

NasdaqGM:TNGX
NasdaqGM:TNGXBiotechs

Is Tango Therapeutics’ New CEO (TNGX) Quietly Redefining Its Clinical Strategy And Execution Priorities?

Tango Therapeutics recently announced that founding CEO Barbara Weber, M.D., has retired as CEO and President, with board member and oncology veteran Malte Peters, M.D., stepping into the President and CEO roles while Dr. Weber shifts to Executive Chair in 2026 and non-executive Chair in 2027. This leadership reshaping, alongside the addition of experienced biopharma finance executive Sung Lee to the board, signals a concerted focus on clinical execution and corporate development...
NYSE:AN
NYSE:ANSpecialty Retail

What AutoNation (AN)'s Bigger Buyback, Jerry’s Toyota Deal and Q4 Date Mean For Shareholders

AutoNation, Inc. recently announced that it will release its fourth-quarter 2025 financial results, for the period ended December 31, 2025, on February 6, 2026, before the market opens, followed by a management conference call and webcast available via its investor relations website. In parallel, JPMorgan upgraded AutoNation while the company moved to acquire Jerry’s Toyota in Baltimore and expanded its share repurchase authorization by US$1.00 billion to about US$1.28 billion, highlighting...
NasdaqGS:RVMD
NasdaqGS:RVMDBiotechs

Is Revolution Medicines (RVMD) Share Price Justified After Strong Multi Year Rally?

If you are wondering whether Revolution Medicines at around US$120 per share reflects its real worth, you are not alone. This article is designed to help you frame that question clearly. The stock closed at US$120.28 recently, with returns of 1.4% over 7 days, 52.7% over 30 days, 52.2% year to date, 198.5% over 1 year and 337.1% over 3 years, which naturally raises questions about how expectations and risk are being priced in. Recent news flow around Revolution Medicines has focused on its...